Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa*

Marrazzi, Mary Ann; Bacon, Jennifer; Kinzie, Jeannie J.; Luby, Elliot D.

doi:10.1097/00004850-199510030-00005

Cited by 105 publications

(39 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Small open trials of naloxone infusions and oral naltrexone have in fact shown consistent weight gain in underweight patients with AN, and may deserve further study. 21 Marrazzi et al 22 did conduct a randomized, double-blind, placebo-controlled study of naltrexone (100 mg twice daily), in which patients receiving active medication showed clinically significant improvement in eating behavior, such as binge eating and purging. The trial was limited, however, by the fact that neither rates nor amounts of weight gain were measured.…”

Section: Opiate Antagonistsmentioning

confidence: 99%

Pharmacologic treatment of anorexia nervosa: Where do we go from here?

Attia

Schroeder

2005

Int. J. Eat. Disord.

View full text Add to dashboard Cite

Section: Opiate Antagonistsmentioning

confidence: 99%

Pharmacologic treatment of anorexia nervosa: Where do we go from here?

Attia

Schroeder

2005

Int. J. Eat. Disord.

View full text Add to dashboard Cite

“…[21][22][23][24] Some clinical studies have suggested that opioid antagonists may have beneficial effects on eating behavior symptoms in patients with eating disorders. 25,26 We have recently completed a genomewide linkage analysis of 192 affected relative pairs with AN and related eating disorders, including bulimia nervosa (BN), which gave only modest evidence for linkage when all DSM-IV eating disorder diagnoses were included in the affected sample. 27,28 Linkage analysis in a subset of 37 families with at least one affected relative pair concordant for a DSM-IV diagnosis of AN, restricting subtype (AN1), showed suggestive evidence for linkage with the highest multipoint NPL score of 3.45 occurring on chromosome 1p33-36 at marker D1S3721, located at B72.6 cM on the human linkage map and B48.1 Mbp on the human genome draft sequence.…”

Section: Introductionmentioning

confidence: 99%

Candidate genes for anorexia nervosa in the 1p33–36 linkage region: serotonin 1D and delta opioid receptor loci exhibit significant association to anorexia nervosa

et al. 2003

View full text Add to dashboard Cite

Serotonergic and opioidergic neurotransmitter system alterations have been observed in people with eating disorders; the genes for the serotonin 1D receptor (HTR1D) and the opioid delta receptor (OPRD1) are found on chr1p36.3-34.3, a region identified by our group in a linkage analysis of anorexia nervosa (AN). These candidate genes were evaluated for sequence variation and for linkage and association of this sequence variation to AN in family and case : control data sets. Resequencing of the HTR1D locus and a portion of the OPRD1 locus identified novel SNPs and confirmed existing SNPs. Genotype assay development and genotyping of nine SNPs (four at HTR1D and five at OPRD1) was performed on 191 unrelated individuals fulfilling DSM-IV criteria (w/o amenorrhea criterion) for AN, 442 relatives of AN probands and 98 psychiatrically screened controls. Linkage analysis of these candidate gene SNPs with 33 microsatellite markers in families including relative pairs concordantly affected with restricting AN (N=37) substantially increased the evidence for linkage of this region to restricting AN to an NPL score of 3.91. Statistically significant genotypic, allelic, and haplotypic association to AN in the case : control design was observed at HTR1D and OPRD1 with effect sizes for individual SNPs of 2.63 (95% CI=1.21-5.75) for HTR1D and 1.61 (95% CI=1.11-2.44) for OPRD1. Using genotype data on parents and AN probands, three SNPs at HTR1D were found to exhibit significant transmission disequilibrium (Po0.05). The combined statistical genetic evidence suggests that HTR1D and OPRD1 or linked genes may be involved in the etiology of AN.

show abstract

“…Finally, patients with BN seem to respond to treatment initially aimed at combatting drug and alcohol abuse. First, Naltrexone, an anti-addiction opioid antagonist normally used in the treatment of alcohol dependence, has shown signs of success in normalizing eating patterns in those su¤ering from anorexia and bulimia (Marrazzi 1995). Second, there are 12-step groups, such as Overeaters Anonymous, based on the recovery program of Alcoholics Anonymous.…”

mentioning

confidence: 99%

Caught in the Bulimic Trap?: Persistence and State Dependence of Bulimia Among Young Women

Goeree¹,

Ham²,

Iorio³

2013

Journal of Human Resources

View full text Add to dashboard Cite

Eating disorders are an important and growing health concern, and bulimia nervosa (BN) accounts for the largest fraction of eating disorders. Health consequences of BN are substantial and especially serious given the increasingly compulsive nature of the disorder. However, remarkably little is known about the mechanisms underlying the persistent nature of BN. Using a unique panel data set on young women and instrumental variable techniques, we document that unobserved heterogeneity plays a role in the persistence of BN, but strikingly up to two thirds is due to true state dependence. Our results, together with support from the medical literature, provide evidence that bulimia should be considered an addiction. Our …ndings have important implications for public policy since they suggest that the timing of the policy is crucial: preventive educational programs should be coupled with more intense (rehabilitation) treatment at the early stages of bingeing and purging behaviors. Our results are robust to di¤erent model speci…cations and identifying assumptions.

show abstract

Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa*

Cited by 105 publications

References 0 publications

Pharmacologic treatment of anorexia nervosa: Where do we go from here?

Pharmacologic treatment of anorexia nervosa: Where do we go from here?

Candidate genes for anorexia nervosa in the 1p33–36 linkage region: serotonin 1D and delta opioid receptor loci exhibit significant association to anorexia nervosa

Caught in the Bulimic Trap?: Persistence and State Dependence of Bulimia Among Young Women

Contact Info

Product

Resources

About